---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000855"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:41:55.235296+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances

## Summary
- Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.
- Submitted Investigator's Brochure for Phase IIa trial in Australia; trial listed on ClinicalTrials.gov; awaiting HREC approval.
- Partnered with BRAINBox Solutions to combine intranasal ONP-002 with diagnostic biomarkers for personalized concussion care.
- Upcoming milestones: HREC approval and first patient enrollment in Q2 2025; Phase IIa enrollment completion by Q4 2025.
- Simplified capital structure by converting all preferred shares to common; annual meeting set for May 2, 2025.

## SEC filing metadata
- accession: 0001641172-25-000855
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/0001641172-25-000855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000164117225000855/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000855
- JSON: https://secwatch.observer/filing/0001641172-25-000855.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.